Recombinant Mumps virus Hemagglutinin-neuraminidase (HN)

What are the primary functional activities of the HN protein?

The HN protein performs two critical enzymatic functions that are essential for mumps virus infectivity:

• Hemagglutinin activity: HN binds to sialic acid-containing receptors on host cells, facilitating viral attachment. This binding is the initial step in the infection process and determines cell tropism .

• Neuraminidase activity: This enzymatic function cleaves sialic acid residues, preventing viral self-aggregation and facilitating viral release from infected cells. Differences in neuraminidase activity between viral strains can affect virulence and tissue tropism .

The dual functionality of HN makes it essential for both the initial stages of infection (attachment) and the final stages (release of progeny virions), making it a central player in the viral life cycle .

How should recombinant HN protein be stored and handled for optimal stability?

For optimal stability and activity preservation, recombinant HN protein should be:

• Initially stored as a lyophilized powder at -20°C/-80°C upon receipt

• Aliquoted after reconstitution to avoid repeated freeze-thaw cycles

• Reconstituted in deionized sterile water to a concentration of 0.1-1.0 mg/mL

• Supplemented with 5-50% glycerol (final concentration) for long-term storage

• Working aliquots can be stored at 4°C for up to one week

The recommended storage buffer is Tris/PBS-based with 6% Trehalose at pH 8.0. Repeated freezing and thawing should be strictly avoided as it leads to protein denaturation and activity loss .

How do mutations in the HN gene affect neurovirulence and viral tropism?

The neurovirulence of mumps virus is significantly influenced by specific mutations in the HN gene. A point mutation from guanine (G) to adenine (A) at nucleotide position 1081 in the HN gene has been directly associated with increased neurovirulence. This mutation corresponds to a glutamic acid (E) to lysine (K) substitution at position 335 in the HN protein .

Structure-function analysis revealed that this E335K mutation alters the protein's surface properties and electrostatic characteristics without affecting the structure of the sialic acid binding motif. The electrostatic surface differs drastically due to changes in an exposed short alpha helix, which affects:

• Sialic acid-binding affinity

• Neuraminidase activity

• Accessibility to substrates and membrane receptors on neuronal cells

Additionally, recent research demonstrates that non-coding regions can also influence neurovirulence. Insertion of non-viral, non-coding 84-nucleotide sequences in the 3' non-coding region (NCR) of the HN gene significantly increases neurovirulence. These insertions provide a replicative advantage in brain tissue and brain-derived cell cultures .

What role does HN protein play in virus-like particle (VLP) production?

HN protein exhibits complex behavior in virus-like particle (VLP) formation, with its contribution varying depending on the viral context:

How does the cooperation between HN and other viral proteins facilitate efficient viral assembly?

The assembly of functional mumps virions requires precise cooperation between multiple viral proteins, primarily:

• Matrix (M) protein: Forms the link between the viral core and membrane

• Nucleocapsid (NP) protein: Encapsidates the viral genome

• Fusion (F) protein: Works with HN for membrane fusion

• HN protein: Mediates attachment and release

In mumps virus, the M protein plays the dominant role in directing virus assembly and budding. The optimal production of mumps VLPs requires the coordinated expression of M, NP, and F proteins, with HN providing an enhancing but non-essential function.

The NP-to-M protein ratio in mumps VLPs is lower than in natural virions, suggesting that while NP is necessary for optimal VLP production, not all VLPs incorporate the same amount of NP protein. This contrasts with other paramyxoviruses like PIV5 and Sendai virus, where VLPs typically contain higher NP-to-M ratios than virions .

What is the current understanding of cross-neutralization between mumps virus variants?

Research on cross-neutralization between human mumps virus variants and related viruses, such as African bat mumps virus (ABMuV), reveals important insights for vaccine development and effectiveness:

• Antibodies induced by either mumps vaccines or infection with wild-type mumps virus can generally neutralize ABMuV efficiently.

• This cross-neutralization suggests significant conservation of immunologically relevant epitopes on the HN protein across different mumps virus strains.

This finding has practical implications for vaccine effectiveness against emerging mumps virus variants and related paramyxoviruses .

What are the optimal expression systems for producing recombinant HN protein?

The choice of expression system significantly impacts the yield, folding, and functionality of recombinant HN protein:

How can researchers effectively analyze mutations in the HN gene and their functional consequences?

A comprehensive approach to analyzing HN mutations should combine multiple methodologies:

• Sequence analysis and structure prediction:

  • Compare sequences between neurovirulent and non-neurovirulent strains

  • Use homology modeling and molecular dynamics simulations to predict structural changes

  • Analyze electrostatic surface properties to identify potential functional alterations

• Functional assays:

  • Hemagglutination assay to measure binding to sialic acid-containing receptors

  • Neuraminidase activity assays using fluorogenic or colorimetric substrates

  • Cell binding and entry assays with various cell types to assess tropism

• In vivo neurovirulence testing:

  • Animal models (particularly newborn rats) to assess differential neurotropism

  • Analysis of virus replication in brain tissue and brain-derived cell cultures

  • Assessment of cytokine induction (particularly RANTES) in infected tissues

• Virus-like particle (VLP) production:

  • Co-expression of mutant HN with other viral proteins to assess assembly efficiency

  • Quantification of VLP release and protein composition

  • Comparison of protein ratios (e.g., NP-to-M ratio) between VLPs with different HN variants

These approaches, used in combination, can reveal how specific mutations alter protein structure, affect protein-protein interactions, and ultimately change viral pathogenicity .

What considerations are important when designing experiments to study HN protein interactions with host receptors?

When investigating HN-receptor interactions, researchers should consider:

• Receptor diversity:

  • Sialic acid receptors vary in linkage (α2,3 vs. α2,6) and distribution across tissues

  • Different cell types express different densities and types of sialic acid-containing molecules

  • Species differences in receptor distribution affect extrapolation from animal models

• Methodology selection:

  • Surface plasmon resonance for direct binding kinetics measurements

  • Glycan arrays to determine specific sialic acid linkage preferences

  • Cell-based binding assays with sialidase treatment controls

  • Competition assays with soluble sialic acid or sialic acid analogs

• Experimental validation:

  • Confirm binding specificity with mutagenesis of key residues in the binding site

  • Use neuraminidase inhibitors to distinguish binding from enzymatic activity

  • Compare results across multiple cell lines and primary cells

• Data interpretation challenges:

  • The dual function of HN (binding and neuraminidase activity) complicates binding studies

  • Binding affinity may be transient due to the protein's enzymatic activity

  • Different methodologies may yield apparently contradictory results based on timing of measurements

Understanding these complexities helps in designing experiments that can accurately characterize how mutations or modifications to the HN protein affect its interactions with host cell receptors, which in turn influences viral tropism and pathogenesis .

How is recombinant HN protein being utilized in vaccine development research?

Recombinant HN protein serves multiple functions in vaccine research:

• Subunit vaccine candidates:

  • Purified recombinant HN protein can elicit neutralizing antibodies

  • Can be combined with adjuvants to enhance immunogenicity

  • Offers potential for safer alternatives to live attenuated vaccines

• Mumps virus as a vaccine vector:

  • The mumps virus genome can be modified to express foreign antigens

  • Understanding HN's contribution to neurovirulence is critical for safe vector design

  • Modifications to the HN gene, including the 3' NCR, can alter viral tropism and safety profile

• Rational attenuation strategies:

  • Knowledge of neurovirulence-associated mutations guides the development of safer live attenuated vaccines

  • E335K mutation and other identified changes can be deliberately avoided in vaccine strains

  • Non-coding region modifications can influence viral behavior without changing protein structure

• Correlates of protection studies:

  • Recombinant HN protein in various assays helps establish antibody correlates of protection

  • Allows comparison of immune responses across different vaccine formulations and wild-type infections

  • Supports investigation of cross-protection against variant strains and related viruses

The ability of antibodies induced by mumps vaccines to cross-neutralize related viruses (such as African bat mumps virus) demonstrates the potential breadth of protection offered by current vaccines and informs the development of next-generation candidates .

What is the potential of HN-modified mumps virus for oncolytic therapy?

Mumps virus shows promise as an oncolytic (cancer-killing) therapeutic agent, with HN modifications playing a key role in specificity and efficacy:

• Tropism engineering:

  • Modifications to the HN protein can alter viral tropism toward cancer cells

  • Understanding neurotropism mechanisms helps design viruses that avoid neural tissue

  • The 3' NCR of the HN gene offers a target for modifying viral behavior without changing protein structure

• Safety considerations:

  • Mutations in HN associated with neurovirulence must be avoided in therapeutic constructs

  • Balancing oncolytic potency with safety requires precise understanding of HN structure-function

  • Insertion of specific sequences in the HN gene can alter viral behavior in predictable ways

• Immune modulation:

  • HN-modified viruses induce specific cytokine profiles (such as RANTES) in infected tissues

  • This immune modulation can be harnessed to enhance anti-tumor responses

  • Tailored modifications can potentially optimize the balance between direct oncolysis and immune activation

• Differential neural cell targeting:

  • Modified viruses with inserts in the HN 3' NCR can infect neurons while being unable to infect astrocytes

  • This selective targeting offers potential for treating specific neural malignancies

  • The molecular basis for this selective tropism requires further investigation

Further research into HN structure-function relationships will enable more precise engineering of mumps virus for cancer therapy applications, balancing efficacy, specificity, and safety .

How do advances in structural biology techniques impact our understanding of HN protein?

Recent advances in structural biology are revolutionizing our understanding of the HN protein:

• Cryo-electron microscopy (cryo-EM):

  • Allows visualization of HN in its native conformation on virus particles

  • Reveals dynamic conformational changes during receptor binding and catalysis

  • Provides insights into the spatial arrangement of HN relative to F protein

• X-ray crystallography:

  • Offers atomic-level resolution of HN protein structure

  • Enables mapping of receptor binding sites and catalytic residues

  • Facilitates structure-based drug design targeting HN

• Molecular dynamics simulations:

  • Predict how mutations alter protein flexibility and surface properties

  • Model the electrostatic surface differences caused by mutations like E335K

  • Simulate interactions between HN and potential receptor molecules or inhibitors

• Integrative structural biology approaches:

  • Combining multiple techniques provides comprehensive structural insights

  • Small-angle X-ray scattering (SAXS) complements crystallography for solution-state analysis

  • Hydrogen-deuterium exchange mass spectrometry reveals dynamics of protein regions

These advanced techniques have demonstrated how mutations like E335K change the protein's electrostatic surface properties without significantly altering the sialic acid binding motif structure, offering mechanistic explanations for observed differences in neurotropism between viral variants .

What insights can be gained from comparative studies of HN proteins across different paramyxoviruses?

Comparative analysis of HN proteins from different paramyxoviruses yields valuable insights:

• Functional conservation and divergence:

  • Despite sequence differences, HN proteins from different viruses (e.g., mumps virus and PIV5) can be functionally interchangeable in certain contexts

  • This suggests conservation of core structural elements and interaction interfaces

  • Specific activities and preferences (receptor binding, neuraminidase activity) may differ significantly

• Evolution of host specificity:

  • Comparison of HN sequences across species-specific paramyxoviruses reveals determinants of host range

  • Similarities between human mumps virus and African bat mumps virus HN explain cross-neutralization

  • Adaptive mutations in emerging viruses can be identified through comparative analysis

• Protein-protein interaction networks:

  • HN proteins interact differently with other viral components across paramyxovirus species

  • In mumps virus, HN is a minor contributor to VLP formation while in PIV5 it is major

  • These differences reflect evolved variations in assembly mechanisms

• Therapeutic target identification:

  • Conserved regions across paramyxovirus HN proteins represent potential broad-spectrum therapeutic targets

  • Unique features of mumps virus HN may be exploited for virus-specific interventions

  • Rational drug design can target either conserved or variable regions depending on desired specificity